Publications

Selected Recent Publications

(Mulligan lab trainees are underlined)

  1. Mulligan LM. Exploiting insights on the RET receptor for personalized cancer medicine (2018). Endocrine Related Cancer. E-pub: May 9 2018 doi:10.1530/ERC-18-0141.
  2. Hyndman BD*, Crupi MJF*, Peng S, Bone LN, Wagner SM, Rekab AN, Antonescu CN, Mulligan LM (2017). Differential recruitment of E3-ubiquitin ligase complexes regulates RET isoform internalization. J Cell Sci 130: 3282-3296. doi:10.1242/jcs.203885.
  3. Maritan SM*, Lian EY*, Mulligan LM (2017). An efficient and flexible cell aggregation method for 3D-spheroid production. Journal of Visualized Experiments (121) e55544, doi:10.3791/55544.
  4. Lian EY, Maritan S, Cockburn JG, Kasaian K, Crupi MJF, Hurlbut D, Jones SJM, Wiseman SM, Mulligan LM (2017). Differential contributions of RET isoforms to medullary and papillary thyroid carcinoma. Endocrine Related Cancer. 24(1): 53-69 DOI:10.1530/ERC-16-0393.
  5. Mulligan LM (2017). Additive effects of gene regulatory variants in multifactorial disease. Journal of Public Health and Emergency. 1: 29. Epub March 15, 2017
  6. Weber F, Mulligan LM (2017). Happy Anniversary MEN1- From positional cloning to gene function restoration. Endocrine Related Cancer 24 (10): E7-E11, doi:10.1530/ERC-17-0346.
  7. Mulligan LM (2016). Progress and potential impact of RET kinase targeting in cancer. Expert Review of Proteomics 13(7): 631-633. DOI: 10.1080/14789450.2016.1205491
  8. Smith J, Read M, Hoffman J, Brown R, Bradshaw B, Campbell C, Cole T, Dieguez Navas J, Eatock F, Gundara J, Lian E, McMullan D, MacDonald F, Morgan N, Mulligan L, Morrison PJ, Robledo M, Simpson M, Smith V, Stewart S, Trembath R, Sidhu S, Togneri F, Vialard L, Wake NC, Wallis Y, Watkinson JC, Maher ER, McCabe C, and Woodward ER (2016). Germline ESR2 Mutation Predisposes to Medullary Thyroid Carcinoma and Causes Up-regulation of RET Expression. Human Molecular Genetics. 25: 1836-1845. DOI: 10.1093/hmg/ddw057.
  9. Wang A, Ramjeesingh R, Chen C-H, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, and Davey S (2016). Reduction in Membranous Immunohistochemical Staining of EpCAM-ICD Correlates with Poor Patient Outcome in Primary Colorectal Adenocarcinoma. Current Oncology. 23(3): e171-e178. DOI: 10.3747/co.23.3028.
  10. Crupi MJF, Yoganathan P, Bone LN, Lian E, Fetz A, Antonescu CN, Mulligan LM (2015). Distinct temporal regulation of RET isoform internalization: roles of clathrin and AP2. Traffic 16: 1155-1173. DOI: 10.1111/tra.12315
  11. Crupi MJF, Richardson DS, Mulligan LM (2015). Cell-Surface Biotinylation of Receptor Tyrosine Kinases to Investigate Intracellular Trafficking. In: Receptor Tyrosine Kinases: Methods and Protocols Ed. Germano, S. Springer Science, New York, USA Methods in Molecular Biology 1233: 91-102. DOI: 10.1007/978-1-4939-1789-1_9
  12. Mulligan LM (2014). RET Revisited: Expanding the Oncogenic Portfolio. Nature Reviews Cancer 14(3): 173-185.
  13. Hyndman BD*, Gujral TS*, Krieger JR, Cockburn JG, Mulligan LM (2013). Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease. Human Mutation. 34 (1): 132-142.
  14. Richardson DS, Rodrigues DM, Hyndman BD, Crupi MJF, Nicolescu AC, Mulligan LM (2012). Alternative splicing results in RET isoforms with distinct trafficking properties. Molecular Biology of the Cell. 23 (19): 3838-3850.
*These authors contributed equally to this work.

(updated 22 May/18)